Literature DB >> 22387067

Intranasal delivery of siRNA to the olfactory bulbs of mice via the olfactory nerve pathway.

Dan B Renner1, William H Frey, Leah R Hanson.   

Abstract

Adopting RNAi technology for targeted manipulation of gene expression in the central nervous system (CNS) will require delivery of RNAi constructs to the CNS followed by cellular transfection and induction of the RNAi machinery. Significant strides have been made in enhancing RNAi transfection and tailoring knockdown toward specific gene targets, however, delivery of the RNAi constructs to the CNS remains a significant challenge. One possible solution for targeting siRNA to the CNS is intranasal administration, which noninvasively delivers a variety of compounds to the CNS. The current study examined delivery of fluorescently labeled siRNA from the nasal cavity to the olfactory bulbs via the olfactory nerve pathway. siRNA was observed along the length of the olfactory nerve bundles, from the olfactory mucosa of the nasal cavity to the anterior regions of the olfactory bulbs. In the olfactory mucosa, labeled siRNA was found within the olfactory epithelium, Bowman's glands, and associated with blood vessels and bundles of olfactory nerves. In the olfactory bulbs, siRNA was observed in the olfactory nerve, glomerular and mitral cell layers. These results demonstrate a role of the olfactory nerve pathway in targeting siRNA to the olfactory bulbs. Additional investigations will be required to assess the distribution of intranasal siRNA to additional regions of the brain and explore the capacity of the delivered siRNA to silence gene expression in the CNS.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22387067     DOI: 10.1016/j.neulet.2012.02.037

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  19 in total

Review 1.  Novel siRNA delivery strategy: a new "strand" in CNS translational medicine?

Authors:  Lisa Gherardini; Giuseppe Bardi; Mariangela Gennaro; Tommaso Pizzorusso
Journal:  Cell Mol Life Sci       Date:  2013-03-19       Impact factor: 9.261

Review 2.  Agile delivery of protein therapeutics to CNS.

Authors:  Xiang Yi; Devika S Manickam; Anna Brynskikh; Alexander V Kabanov
Journal:  J Control Release       Date:  2014-06-21       Impact factor: 9.776

3.  Selective α-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson's Disease.

Authors:  Diana Alarcón-Arís; Ariadna Recasens; Mireia Galofré; Iria Carballo-Carbajal; Nicolás Zacchi; Esther Ruiz-Bronchal; Rubén Pavia-Collado; Rosario Chica; Albert Ferrés-Coy; Marina Santos; Raquel Revilla; Andrés Montefeltro; Isabel Fariñas; Francesc Artigas; Miquel Vila; Analia Bortolozzi
Journal:  Mol Ther       Date:  2017-11-29       Impact factor: 11.454

4.  Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I.

Authors:  Lalitha R Belur; Alexa Temme; Kelly M Podetz-Pedersen; Maureen Riedl; Lucy Vulchanova; Nicholas Robinson; Leah R Hanson; Karen F Kozarsky; Paul J Orchard; William H Frey; Walter C Low; R Scott McIvor
Journal:  Hum Gene Ther       Date:  2017-04-20       Impact factor: 5.695

5.  Nanotechnology for CNS delivery of bio-therapeutic agents.

Authors:  Lipa Shah; Sunita Yadav; Mansoor Amiji
Journal:  Drug Deliv Transl Res       Date:  2013-08-01       Impact factor: 4.617

Review 6.  Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases.

Authors:  Kavitha Siva; Giuseppina Covello; Michela A Denti
Journal:  Nucleic Acid Ther       Date:  2014-02       Impact factor: 5.486

Review 7.  Intranasal Insulin: a Treatment Strategy for Addiction.

Authors:  Bhavani Kashyap; Leah R Hanson; William H Frey Ii
Journal:  Neurotherapeutics       Date:  2020-01       Impact factor: 7.620

8.  Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders.

Authors:  K Macdonald; D Feifel
Journal:  Front Neurosci       Date:  2013-03-15       Impact factor: 4.677

9.  Intranasal, siRNA Delivery to the Brain by TAT/MGF Tagged PEGylated Chitosan Nanoparticles.

Authors:  Meenakshi Malhotra; Catherine Tomaro-Duchesneau; Shyamali Saha; Satya Prakash
Journal:  J Pharm (Cairo)       Date:  2013-09-12

10.  siRNA Treatment: "A Sword-in-the-Stone" for Acute Brain Injuries.

Authors:  Andrew M Fukuda; Jerome Badaut
Journal:  Genes (Basel)       Date:  2013-09-05       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.